Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
03 July 2023 | Story Leonie Bolleurs | Photo Stephen Collett
Prof Oliver Mutanga and Prof Melanie Walker
Prof Oliver Mutanga, one of the first PhD gradautes under the SARChI Chair in Higher Education and Human Development, pictured with his former supervisor, Prof Melanie Walker, during his first visit to the university after ten years.

Prof Oliver Mutanga, a University of the Free State (UFS) alumnus with a PhD in Development Studies and an experienced researcher focused on matters pertaining to disability, education, equality, and health issues, recently took up the position of Assistant Professor in the Graduate School of Education at the Nazarbayev University in Astana, Kazakhstan.

Prof Melanie Walker, Director of the SARChI Chair in Higher Education and HumanDevelopment (HEHD) at the UFS, invited Prof Mutanga to discuss his own research via an open webinar and to engage with members of her research group.

Prof Walker explained that she was delighted to host Dr Mutanga at the university, given his profile as an outstanding and internationally mobile early career researcher, from whom others in her group could learn. “Further, I very much wanted Dr Mutanga to speak about his own research, given its overall academic excellence, quality, and impact. Going forward, I am looking forward to developing this link with Dr Mutanga and his colleagues abroad around critical diversity studies,” she states.

Profs Walker and Mutanga have collaborated in the past to write articles for academic journals arising from his doctoral research. Examples include, ‘Towards a disability-inclusive higher education policy through the capabilities approach’ (published in the Journal of Human Development and Capabilities) as well as ‘Exploration of the academic lives of students with disabilities at South African universities: Lecturers’ perspectives’ (published in the African Journal of Disability).

Prior to joining Nazarbayev University, Prof Mutanga gained valuable research and development experience in various countries, including Zimbabwe, Botswana, South Africa, Norway, and the United Kingdom.

He has also received several accolades for his work, including the prestigious Marie Sklodowska Curie Postdoctoral Fellowship at the University of Oslo, Norway, and the Global Challenges Research Fellowship at University College London's Institute of Education.

A unique outlook on disability

In 2013, Prof Mutanga was part of the first cohort of PhD students under the SARChI Chair in Higher Education and Human Development. Recently, during his three-day visit to the UFS, he addressed the HEHD research group and an international academic audience during a hybrid seminar on the perceptions and experiences of disability within the Tembo Mvura communities of Northern Zimbabwe.

In his research for this paper, Prof Mutanga uses storytelling and in-depth interviews to offer a distinctive, community-based, and Southern interpretation of disability. By applying the capabilities approach and the ubuntu philosophy, his study presents a contrast to Western perceptions of disability that often emphasise individual limitations and differences based on physical and mental characteristics, which have the potential to both result in isolation and to understanding people as autonomous but isolated beings.

Within the Tembo Mvura communities, he discovered that disability is viewed through a lens of interconnectedness between individuals, their environment, and the spiritual world: “They recognise the inherent worth and dignity of all individuals, irrespective of their impairments,” found Prof Mutanga. Indeed, impairment of full personhood is understood as lacking in any of the three dimensions outlined above.

Thus, Prof Mutanga explored the complex interaction of identity, access to land, laws, and language, as well as labelling, highlighting how these factors shape perceptions and experiences of disability within these communities.

He is of the view that these findings will have implications for North-dominated disability discourse and for policy, practice, and research within indigenous contexts, such as the Tembo Mvura, where disability is uniquely perceived and experienced.

In addition to the hybrid seminar, Prof Mutanga led valuable sessions with the HEHD Research Group, where the PhD and postdoctoral fellows had the opportunity to workshop and refine various aspects of their current research papers and to engage in discussions around building their academic careers.

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept